source
- Novo pays $300 million upfront to license Hengrui’s weekly oral GLP-1/GIP weight-loss drugNovo Nordisk announced a licensing agreement with Chinese drugmaker Hengrui for a preclinical weekly oral GLP-1/GIP receptor agonist aimed at weight loss. The deal involves an upfront payment of $…
- FDA approves Egetis Therapeutics' Emcitate for rare X linked disease shortening life expectancy to 35 yearsEgetis Therapeutics announced that the U.S. Food and Drug Administration has granted approval for its drug Emcitate. The therapy is intended for patients with a rare X linked genetic disorder that…